Response Biomedical CEO resigns

Jeffrey Purvin recently resigned from the board of directors and as the president and CEO of Response Biomedical Corp. effective immediately. 

Dr. Anthony Holler, a long-time Response board member, will serve as interim CEO. In addition, Barbara Kinnaird has been promoted from vice president to chief operating officer. 

"We thank Jeff Purvin for his efforts at Response over the past two years," Lewis Shuster, the chairman of Response, said. "We welcome Dr. Tony Holler to his new role as interim CEO. He knows the company intimately from his long history as a director.

Holler joined Response’s board of directors in March 2006. He was one of the original founders of ID Biomedical Corporation and has served as its director since 1991. He served as CEO from 1999 until 2006 when GlaxoSmithKline acquired the company. 

Kinniard has held several key management positions in product development, quality, regulatory, manufacturing and sales since joining Biomedical Corp. in 2004. 

"Response's gross margins have improved substantially under (Kinniard's) leadership...," Holler said. "Gross margin improved from negative 5 percent in 2010 to positive 45 percent in our last quarter as her team has implemented numerous steps to improve quality, strengthen internal operations and boost productivity."

Organizations in this Story

Response Biomedical

Want to get notified whenever we write about Response Biomedical ?
Next time we write about Response Biomedical, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.